Cyteir Therapeutics, Inc. Common Stock
CYT
CYT was delisted on the 15th of March, 2024.
48 hedge funds and large institutions have $253M invested in Cyteir Therapeutics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 16 increasing their positions, 9 reducing their positions, and 2 closing their positions.
500% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 2
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
78% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 9
26% more funds holding
Funds holding: 38 → 48 (+10)
7.58% more ownership
Funds ownership: 55.6% → 63.17% (+7.6%)
26% less capital invested
Capital invested by funds: $344M → $253M (-$90.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$2.53M |
| 2 |
BlackRock
New York
|
+$2.3M |
| 3 |
Morgan Stanley
New York
|
+$1.28M |
| 4 |
Millennium Management
New York
|
+$790K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$660K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.61M |
| 2 |
CCM
CAAS Capital Management
New York
|
-$1.56M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$1.02M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$553K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$482K |
CYT Hedge Fund Activity: Q4 2021 in Review
48 of the 6,521 institutional investors tracked by Wall St. Rank reported a position in Cyteir Therapeutics, Inc. Common Stock (CYT) for Q4 2021, worth a combined $253M — down 26% from $344M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new CYT positions and 2 closed out — a net gain of 10 holders — while 16 added to existing stakes and 9 trimmed.
The largest buyer was Avidity Partners Management, adding an estimated $2.53M. The largest seller was Fidelity Investments, cutting an estimated $3.61M.
- 48 institutional investors held Cyteir Therapeutics, Inc. Common Stock (CYT) as of Q4 2021, up from 38 in Q3 2021.
- Funds reported $253M of Cyteir Therapeutics, Inc. Common Stock stock for Q4 2021, down 26% quarter-over-quarter.
- 12 funds opened new Cyteir Therapeutics, Inc. Common Stock positions in Q4 2021 and 2 closed out, a net change of +10 holders.
- The largest Cyteir Therapeutics, Inc. Common Stock buyer in Q4 2021 was Avidity Partners Management, an estimated $2.53M added.
- The largest Cyteir Therapeutics, Inc. Common Stock seller in Q4 2021 was Fidelity Investments, an estimated $3.61M sold.
Based on aggregated 13F filings for Q4 2021.